Merck & Co logo

Merck & Co

Stock
Stock
ISIN: US58933Y1055
Ticker: MRK
US58933Y1055
MRK

Price

Price

Historical dividends and forecast

All dividend data

Merck & Co has so far distributed $3.08 in 2024. The next dividend will be paid on 08.01.2025


$1.444

CHART BY

Frequently asked questions

What is Merck & Co's market capitalization?

The market capitalization of Merck & Co is $252.61B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is Merck & Co's Price-to-Earnings (P/E) ratio?

The Price-to-Earnings (P/E) ratio (TTM) for Merck & Co is 20.94. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.

What is the Earnings Per Share (EPS) for Merck & Co?

Merck & Co's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $4.768. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Merck & Co's stock?

Currently, 25 analysts cover Merck & Co's stock, with a consensus target price of $141.22. Analyst ratings provide insights into the stock's expected performance.

What is Merck & Co's revenue over the trailing twelve months?

Over the trailing twelve months, Merck & Co reported a revenue of $63.17B.

Is Merck & Co paying dividends?

Yes, Merck & Co is paying dividends. The next payment is scheduled for 08.01.2025, with an expected amount of .

What is the EBITDA for Merck & Co?

Merck & Co's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $28.21B. EBITDA measures the company's overall financial performance.

What is the free cash flow of Merck & Co?

Merck & Co has a free cash flow of $7.10B. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Merck & Co's stock?

The 5-year beta for Merck & Co is 0.41. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Merck & Co have, and what sector and industry does it belong to?

Merck & Co employs approximately 72,000 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Merck & Co's shares?

The free float of Merck & Co is 2.53B. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 
$252.61B

5Y beta

 
0.41

EPS (TTM)

 
$4.768

Free Float

 
2.53B

P/E ratio (TTM)

 
20.94

Revenue (TTM)

 
$63.17B

EBITDA (TTM)

 
$28.21B

Free Cashflow (TTM)

 
$7.10B

Pricing

1D span
$99.14$101.13
52W span
$94.48$134.63

Analyst Ratings

The price target is $141.22 and the stock is covered by 25 analysts.

Buy

20

Hold

5

Sell

0

Information

Merck & Co., Inc. is a research-intensive biopharmaceutical company engaged in research to deliver health solutions that advance the prevention and treatment of diseases in people and animals. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. It is also engaged in developed a novel class of small molecules that target cancer cells lacking expression of a key DNA repair protein called O6-methylguanine methyl transferase.

72,000

Biotechnology & Drugs

Health Care

Identifier

ISIN

US58933Y1055

Primary Ticker

MRK

Knockouts

Join the conversation